ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd., have responded to the European Society of Hypertension's (ESH) updated guidelines for the management of arterial hypertension. The ESH guidelines now endorse renal denervation as a treatment option for patients with resistant or uncontrolled hypertension despite medication use. ReCor Medical has conducted clinical trials on their Paradise™ Ultrasound Renal Denervation System and is currently seeking approval from the U.S. Food and Drug Administration (FDA).
Treating hypertension can be complex, but the updated guidelines from the ESH reinforce the safety and effectiveness of renal denervation as a treatment option to improve hypertension control. Both ReCor Medical and Otsuka Medical Devices are pleased to see these recommendations, as they provide healthcare professionals with the latest scientific evidence for treating hypertension worldwide.